Xue Jun-Fa, Li Dong-Fang, Wang Ya-Ni, Chen Chen, Yang Ru-Fei, Zhou Qing-Jun, Liu Ting, Xie Li-Xin, Dong Yan-Ling
School of Medicine and Life Sciences, Shandong First Medical University, Jinan 271016, Shandong Province, China.
State Key Laboratory Cultivation Base, Shandong Province Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Qingdao 266071, Shandong Province, China.
Int J Ophthalmol. 2021 Nov 18;14(11):1690-1699. doi: 10.18240/ijo.2021.11.07. eCollection 2021.
To evaluate the midterm outcomes of penetrating keratoplasty (PK) following allogeneic cultivated limbal epithelial transplantation (CLET) for bilateral total limbal stem cell deficiency (LSCD).
Ten patients (10 eyes) with bilateral LSCD were enrolled in this prospective noncomparative case series study. Each participant underwent PK approximately 6mo after a CLET. Topical tacrolimus, topical and systemic steroids, and oral ciclosporin were administered postoperatively. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), ocular surface grading scores (OSS), corneal graft epithelial rehabilitation, persistent epithelial defect (PED), immunological rejection, and graft survival rate were assessed.
The time interval between PK and allogeneic CLET was 6.90±1.29 (6-10)mo. BCVA improved from 2.46±0.32 logMAR preoperatively to 0.77±0.55 logMAR post-PK (<0.001). Kaplan-Meier analysis of mean graft survival revealed graft survival rates of 100% at 12 and 24mo and 80.0% at 36mo. PEDs appeared in 5 eyes at different periods post-PK, and graft rejection occurred in 4 eyes. The total OSS decreased from 12.4±4.4 before allogeneic CLET to 1.4±1.51 after PK.
A sequential therapy design of PK following allogeneic CLET can maintain a stable ocular surface with improved BCVA despite the relatively high graft rejection rate.
评估异体培养角膜缘上皮移植(CLET)治疗双眼全角膜缘干细胞缺乏(LSCD)后穿透性角膜移植术(PK)的中期效果。
本前瞻性非对照病例系列研究纳入了10例(10眼)双眼LSCD患者。每位参与者在CLET术后约6个月接受PK。术后给予局部他克莫司、局部和全身类固醇以及口服环孢素。评估最佳矫正视力(BCVA)、眼压(IOP)、眼表分级评分(OSS)、角膜移植上皮修复情况、持续性上皮缺损(PED)、免疫排斥反应和移植存活率。
PK与异体CLET之间的时间间隔为6.90±1.29(6 - 10)个月。BCVA从术前的2.46±0.32 logMAR提高到PK术后的0.77±0.55 logMAR(<0.001)。平均移植存活率的Kaplan-Meier分析显示,12个月和24个月时移植存活率为100%,36个月时为80.0%。PK术后不同时期有5只眼出现PED,4只眼发生移植排斥反应。总的OSS从异体CLET前的12.4±4.4降至PK后的1.4±1.51。
异体CLET后序贯PK治疗设计尽管移植排斥率相对较高,但可维持稳定的眼表并提高BCVA。